• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病神经病变中的血管钙化与骨质溶解——核因子κB受体活化因子配体(RANK-L)是其中的关键环节吗?

Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?

作者信息

Jeffcoate W

机构信息

Foot Ulcer Trials Unit, Department of Diabetes and Endocrinology, City Hospital, NG5 1PB, Nottingham, UK.

出版信息

Diabetologia. 2004 Sep;47(9):1488-92. doi: 10.1007/s00125-004-1477-5. Epub 2004 Aug 21.

DOI:10.1007/s00125-004-1477-5
PMID:15322748
Abstract

Diabetic neuropathy is associated with osteopenia and calcification of vascular smooth muscle cells. These changes are most marked in patients with acute neuropathic osteoarthropathy (Charcot foot), in which osteopenia is universal and the prevalence of vascular calcification exceeds 90%. While it has been thought that both osteopenia and vascular calcification may be linked to sympathetic denervation with increased peripheral limb perfusion, the cellular mechanism was not clear. However, the recent recognition that the receptor activator of nuclear factor kappa B ligand (RANK-L)/osteoprotegerin (OPG) signalling pathway is central to the processes regulating bone turnover in a wide variety of medical conditions has raised the possibility that the same cytokines may be involved in the osteolysis which accompanies diabetic neuropathy. This is made more likely by the realisation that the RANK-L/OPG pathway is also thought to mediate the calcification of vascular smooth muscle cells in coronary and peripheral vascular disease. The circumstantial evidence underpinning this hypothesis is reviewed here, and it is suggested that the unregulated activation of RANK-L-mediated effects on bone and arteries may be triggered by the loss of nerve-derived peptides, e.g. calcitonin gene-related peptide, which normally exert a moderating influence on the pathway.

摘要

糖尿病神经病变与骨量减少及血管平滑肌细胞钙化有关。这些变化在急性神经性骨关节病(夏科氏足)患者中最为明显,其中骨量减少普遍存在,血管钙化的发生率超过90%。虽然一直认为骨量减少和血管钙化都可能与交感神经去神经支配及外周肢体灌注增加有关,但其细胞机制尚不清楚。然而,最近认识到核因子κB受体活化因子配体(RANK-L)/骨保护素(OPG)信号通路在多种医学病症中调节骨转换的过程中起核心作用,这增加了同一细胞因子可能参与伴随糖尿病神经病变的骨质溶解的可能性。由于认识到RANK-L/OPG通路也被认为在冠状动脉和外周血管疾病中介导血管平滑肌细胞的钙化,这种可能性更大。本文综述了支持这一假说的间接证据,并提出RANK-L介导的对骨骼和动脉的影响的失控激活可能是由神经源性肽(如降钙素基因相关肽)的丧失引发的,而神经源性肽通常对该通路起调节作用。

相似文献

1
Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?糖尿病神经病变中的血管钙化与骨质溶解——核因子κB受体活化因子配体(RANK-L)是其中的关键环节吗?
Diabetologia. 2004 Sep;47(9):1488-92. doi: 10.1007/s00125-004-1477-5. Epub 2004 Aug 21.
2
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.破骨细胞调节因子RANKL和骨保护素对血管钙化的调节作用
Circ Res. 2004 Nov 26;95(11):1046-57. doi: 10.1161/01.RES.0000149165.99974.12.
3
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.白细胞介素-6与前列腺素E2信号系统之间的相互作用,通过影响骨保护素/核因子-κB受体激活因子配体(RANKL)/核因子-κB受体激活因子(RANK)系统,导致破骨细胞生成增强。
Endocrinology. 2005 Apr;146(4):1991-8. doi: 10.1210/en.2004-1167. Epub 2004 Dec 23.
4
The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.骨保护素/骨保护素配体家族:在炎症和骨质流失中的作用
J Rheumatol. 2004 May;31(5):844-6.
5
Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.骨保护素、核因子κB受体活化因子(RANK)及RANK配体:类风湿关节炎中的善、恶与丑
J Rheumatol. 2001 Apr;28(4):685-7.
6
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.骨保护素和核因子κB受体活化因子配体调节骨吸收、骨密度、骨几何形态和骨强度。
Curr Opin Pharmacol. 2005 Dec;5(6):618-25. doi: 10.1016/j.coph.2005.06.005. Epub 2005 Sep 26.
7
Bone cancer pain and the role of RANKL/OPG.骨癌疼痛与核因子κB受体活化因子配体/骨保护素的作用
J Musculoskelet Neuronal Interact. 2004 Sep;4(3):293-300.
8
Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis.牙发育中的骨保护素、核因子κB受体活化因子及其配体:牙发生与骨发生的协调
J Dent Res. 2004 Mar;83(3):241-4. doi: 10.1177/154405910408300311.
9
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.骨保护素/RANKL/RANK系统对骨骼和血管疾病的临床意义。
JAMA. 2004 Jul 28;292(4):490-5. doi: 10.1001/jama.292.4.490.
10
Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.抗RANKL疗法治疗炎症性骨病:作用机制及潜在临床应用
J Cell Biochem. 2006 Feb 1;97(2):226-32. doi: 10.1002/jcb.20674.

引用本文的文献

1
The diabetic neuropathy and bone mineral density in type 2 diabetes mellitus: a cross-sectional and meta-analytic study.2型糖尿病患者的糖尿病神经病变与骨密度:一项横断面及荟萃分析研究
Clin Exp Med. 2025 May 25;25(1):175. doi: 10.1007/s10238-025-01710-2.
2
Prevalence of Osteoporosis in Postmenopausal Type 2 Diabetic Women with Diabetic Peripheral Neuropathy.绝经后2型糖尿病合并糖尿病周围神经病变女性的骨质疏松患病率
Indian J Endocrinol Metab. 2025 Jan-Feb;29(1):55-60. doi: 10.4103/ijem.ijem_108_24. Epub 2025 Feb 28.
3
[Etiopathogenetic features of bone metabolism in patients with diabetes mellitus and Charcot foot].

本文引用的文献

1
New insights into the molecular mechanisms of action of bisphosphonates.双膦酸盐作用分子机制的新见解。
Curr Pharm Des. 2003;9(32):2643-58. doi: 10.2174/1381612033453640.
2
The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis.长期血液透析患者血管钙化进展与血清骨保护素水平
Am J Kidney Dis. 2003 Aug;42(2):303-9. doi: 10.1016/s0272-6386(03)00655-3.
3
Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.破骨细胞和成牙骨质细胞在矿化组织吸收中的分化及功能
[糖尿病和夏科氏足患者骨代谢的病因发病学特征]
Probl Endokrinol (Mosk). 2024 Sep 15;70(4):57-64. doi: 10.14341/probl13362.
4
Cartilage Damage Pathological Characteristics of Diabetic Neuropathic Osteoarthropathy.糖尿病神经病变性骨关节病的软骨损伤病理特征。
Anal Cell Pathol (Amst). 2023 May 8;2023:7573165. doi: 10.1155/2023/7573165. eCollection 2023.
5
Acute Charcot arthropathy as a first presentation of type 2 diabetes mellitus.急性夏科氏关节炎作为 2 型糖尿病的首发表现。
BMJ Case Rep. 2023 Feb 20;16(2):e253544. doi: 10.1136/bcr-2022-253544.
6
Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus.糖尿病性活跃性夏科氏神经关节病中炎症和破骨细胞生成的差异缓解对足部长期结局的影响。
PLoS One. 2021 Nov 8;16(11):e0259224. doi: 10.1371/journal.pone.0259224. eCollection 2021.
7
Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review.1型和2型糖尿病神经病变的异同:一项系统评价
J Pers Med. 2021 Mar 22;11(3):230. doi: 10.3390/jpm11030230.
8
How We Manage Bone Marrow Edema-An Interdisciplinary Approach.我们如何管理骨髓水肿——一种跨学科方法。
J Clin Med. 2020 Feb 18;9(2):551. doi: 10.3390/jcm9020551.
9
Neuroarthropathy in diabetes: pathogenesis of Charcot arthropathy.糖尿病性神经关节病:夏科关节病的发病机制
Bone Joint Res. 2018 Jun 5;7(5):373-378. doi: 10.1302/2046-3758.75.BJR-2017-0334.R1. eCollection 2018 May.
10
Pathogenesis and potential relative risk factors of diabetic neuropathic osteoarthropathy.糖尿病性神经性骨关节病的发病机制及潜在相关危险因素
J Orthop Surg Res. 2017 Oct 2;12(1):142. doi: 10.1186/s13018-017-0634-8.
Microsc Res Tech. 2003 Aug 15;61(6):483-95. doi: 10.1002/jemt.10370.
4
Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications.患有微血管并发症的2型糖尿病患者血浆骨保护素浓度升高。
Eur J Endocrinol. 2003 Jul;149(1):39-42. doi: 10.1530/eje.0.1490039.
5
Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.高磷酸盐浓度对破骨细胞分化以及骨吸收活性的影响。
J Cell Physiol. 2003 Jul;196(1):180-9. doi: 10.1002/jcp.10270.
6
The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis.心血管自主神经病变与糖尿病患者死亡率之间的关联:一项荟萃分析。
Diabetes Care. 2003 Jun;26(6):1895-901. doi: 10.2337/diacare.26.6.1895.
7
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.骨病的病因及双膦酸盐在多发性骨髓瘤中的作用。
Lancet Oncol. 2003 May;4(5):284-92. doi: 10.1016/s1470-2045(03)01076-3.
8
Arterial calcification in diabetes.糖尿病中的动脉钙化
Curr Diab Rep. 2003 Feb;3(1):28-32. doi: 10.1007/s11892-003-0049-2.
9
Increased osteoprotegerin serum levels in men with coronary artery disease.冠心病男性患者血清骨保护素水平升高。
J Clin Endocrinol Metab. 2003 Mar;88(3):1024-8. doi: 10.1210/jc.2002-020775.
10
Bisphosphonate mechanism of action.双膦酸盐的作用机制。
Curr Rheumatol Rep. 2003 Feb;5(1):65-74. doi: 10.1007/s11926-003-0085-6.